Prognostic and predictive value of Pleckstrin homology-like domain, family A family members in breast cancer
Autor: | Iberê C. Soares, Daniel Rodrigues de Bastos, Suely Nonogaki, F. R. R. Mangone, Evandro Sobroza de Mello, Ana Carolina Pavanelli, Maria Aparecida Nagai, Cynthia Ab de T Osório, Renan G do Nascimento, Mércia Pf Conceição, Maira Av Valoyes |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
0301 basic medicine In silico Clinical Biochemistry Gene Expression Breast Neoplasms Cohort Studies 03 medical and health sciences 0302 clinical medicine Breast cancer Drug Discovery Biomarkers Tumor Humans Medicine Gene family Protein kinase B Tissue microarray business.industry Kinase Biochemistry (medical) Nuclear Proteins Middle Aged Prognosis medicine.disease Immunohistochemistry Gene Expression Regulation Neoplastic Pleckstrin homology domain 030104 developmental biology 030220 oncology & carcinogenesis Cancer research Hormonal therapy Transcriptome business Proto-Oncogene Proteins c-akt Brazil Signal Transduction Transcription Factors |
Zdroj: | Biomarkers in Medicine. 14:1537-1552 |
ISSN: | 1752-0371 1752-0363 |
DOI: | 10.2217/bmm-2020-0417 |
Popis: | Aim: The PHLDA (pleckstrin homology like domain, family A) gene family encodes proteins capable of inhibiting AKT (serine/threonine kinase) signaling through phosphoinositol binding competition. Results & methodology: Using in silico analysis, we found that Luminal A and B patients' short relapse-free survival was associated with low PHLDA1 or PHLDA3 and high PHLDA2 expression. In a cohort of 393 patients with luminal breast cancer evaluated by immunohistochemistry on tissue microarrays, we found a direct association of PHLDA3 expression with hormonal therapy response (p = 0.013). Conclusion: Our findings provide new information on the role played by the PHLDA family members as prognostic markers in breast cancer, and more importantly, we provide evidence that they might also predict a response to endocrine therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |